Suellen Anne Lyne

Suellen Anne Lyne

Auto-generated profile, based on publicly available information

Suellen Anne Lyne

Adelaide Medical School, The University of Adelaide, North Terrace, Adelaide, 5005, Australia; The Queen Elizabeth Hospital, 28 Woodville Road, Woodville South, 5011, Adelaide, Australia; Flinders Medical Centre, Flinders Drive, Bedford Park, 5042, Australia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2023 in Rheumatology
Verified
Journal Article
Open access
PDF file
SBSusan Bridgewater
Susan Bridgewater
MSMichael A Shepherd
Michael A Shepherd
JDJill Dawson
Jill Dawson
PRPamela Richards
Pamela Richards
CSChristine Silverthorne
Christine Silverthorne
JRJoanna C Robson
Joanna C Robson
Glucocorticoids (GCs) (‘steroids’) are used to treat rheumatic diseases but adverse effects are common. We aimed to explore the impact of GC therapy on health-related quality of life (HRQoL), to inform the development of a treatment-specific patient-reported outcome measure (PROM) for use in clinical trials and practice. Semi-structured qualitative interviews were conducted with patients from the UK, USA and Australia, treated for a rheumatic condition with GCs in the last 2 years. Purposive sampling was used to select participants with a range of demographic and disease features. An initial conceptual framework informed interview prompts and cues. Interviews elicited GC-related physical and psychological symptoms and salient aspects of HRQoL in relation to GC therapy. Interview data were analysed inductively to develop initial individual themes and domains. Candidate questionnaire items were developed and refined. Sixty semi-structured qualitative interviews were conducted (UK n = 34, USA n = 10, Australia n = 16). The mean age was 58 years; 39/60 were female; and 18 rheumatic diseases were represented. Some 126 individual themes were identified and organized into six domains: physical symptoms; psychological symptoms; psychological impact of steroids; impact of steroids on participation; impact of steroids on relationships; and benefits of steroids. Candidate questionnaire items were tested and refined by piloting with patient research partners, iterative rounds of cognitive interviews and linguistic translatability assessment, informing a draft questionnaire. We describe an international qualitative study to develop candidate items for a treatment-specific PROM for patients with rheumatic diseases. A future survey will enable the validation of a final version of the PROM.

16 December 2023 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Open access
SLSuellen A. Lyne
Suellen A. Lyne
KYKevin Yip
Kevin Yip
VVVasilis S. Vasiliou
Vasilis S. Vasiliou
DKDavid A. Katz
David A. Katz
PRPamela Richards
Pamela Richards
CHCatherine L Hill
Catherine L Hill
Background: The Outcome Measures in Rheumatology (OMERACT) Glucocorticoid (GC) Impact Working Group has been working to develop a core domain set to measure the impact of GCs on patients living with rheumatic and musculoskeletal diseases. The mandatory domains previously identified for inclusion in all clinical trials measuring the GC effects include infection, bone fragility, mood disturbance, hypertension, diabetes, weight, fatigue, and mortality. Before progressing to instrument selection, the Working Group sought to establish precise definitions of all mandatory domains within the core domain set. Methods: OMERACT methodology was applied with the use of evidence and consensus-based decision making of all stakeholder groups (patient research partners, health care professionals, clinician researchers, industry members and methodologists) to develop detailed definitions for the broad domain, target domain and domain components, taking into consideration sources of variability that could affect measurement of the domain. The working group synthesized prior qualitative studies, quantitative work, and results from Delphi rounds, to develop a rich definition of ‘what’ is to be measured. Results: Between 2021 and2023, the OMERACT Working Group on GC Impact conducted virtual meetings to establish domain definitions. First, we mapped each domain onto an OMERACT Core Area. All domains were primarily represented within the Pathophysiological Manifestations Core Area, except from Fatigue which was primarily Life Impact and Weight which spanned both Core Areas. Sources of variability included cultural factors, age, gender, education level, socioeconomic status, personal experiences, emotional state, and language barriers. The domain definitions will form the foundation for instrument selection and the initial step of domain / concept match and content validity in the OMERACT pillar of ‘truth’ before moving on to feasibility and discrimination. Conclusion: The OMERACT GC Impact Working Group has developed and agreed upon detailed domain definitions for core domains. Future steps of the working group are to select instruments and develop the core outcome measurement set for clinical trials measuring the impact of GC on patients with rheumatic and musculoskeletal diseases.

2 January 2026 in Rheumatology Advances in Practice
Verified
Journal Article
Open access
SLSuellen Anne Lyne
Suellen Anne Lyne
CRCarlee Deanne Ruediger
Carlee Deanne Ruediger
CHCatherine Louise Hill
Catherine Louise Hill
ESE Michael Shanahan
E Michael Shanahan
Objective: The impact of GCA and its treatment on an individual’s life is poorly characterised. This research sought to advance existing qualitative literature to tailor better diagnostic frameworks, treatment approaches and therapeutic relationships that focus on outcomes that are important to patients. Methods: A qualitative study using phenomenology was undertaken. Purposive sampling selected recently diagnosed participants with varied experiences, including those with and without a confirmatory diagnostic test, vision loss, prednisolone adverse effects and psychosocial impact. Semi-structured interviews were conducted until saturation. Themes emerged through data interpretation, bringing together common experiences and their variant manifestations to elucidate the lived experience of GCA. Results: Of 34 individuals invited, 20 agreed to participate; 12 (60%) were female, median age at diagnosis 68 years (range 58–86) and mean time since diagnosis 15.7 months (range 1–45). Four main themes emerged: living with uncertainty and fear, change in self-perception and loss of autonomy, adapting to physical symptoms and the critical importance of the healthcare interaction. Conclusion: This study provides unique insights into the lived experiences of individuals with recently diagnosed GCA. Our findings emphasise the profound psychological and functional impact of GCA and recognise the critical importance of patient experience on overall well-being. These insights demand we move towards a patient-centred model of care that goes beyond disease control, prioritising clear communication, tailored patient education, support networks and integrated service provision. Addressing these unmet needs represents a critical opportunity to improve outcomes that are important to people living with GCA.

18 March 2026 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Open access
SLSuellen Anne Lyne
Suellen Anne Lyne
SLSusan Lester
Susan Lester
JSJessica Stanhope
Jessica Stanhope
JTJoanna Tieu
Joanna Tieu
KDKathryn Ann Dyer
Kathryn Ann Dyer
CHCatherine Louise Hill
Catherine Louise Hill
Giant cell arteritis (GCA) causes significant morbidity from disease burden and treatment complications, yet Australian data on healthcare utilisation are lacking. This study quantified healthcare utilisation among patients with biopsy-proven GCA in South Australia (SA) by examining rates and causes of hospitalisation and emergency department (ED) presentation, temporal trends, length of stay, and cumulative comorbidity burden. Patients aged ≥50 years with positive temporal artery biopsy were identified from the SA GCA Registry (1992-2022). ED presentations and hospital admissions (2001-2022) were obtained using the SA-NT Data-linkage framework, and compared against controls (4:1) from the same sociodemographic distribution. Recurrent event Andersen-Gill time-to-event models estimated Hazard Ratios (HR). Cumulative Elixhauser comorbidity scores were determined at last visit as a surrogate for patients' overall health status. 435 GCA patients and 2124 controls were included. Both ED presentations and hospital admissions were increased in GCA patients compared to controls (HR 1.74 (95%CI 1.48, 2.03) and HR 1.73 (95%CI 1.14, 2.61)), with events highest within 12 months of GCA diagnosis. Mean length of stay was equivalent. GCA patients more often had a principal admission diagnosis of infection (HR 1.53, 95%CI 1.12, 2.09), cerebrovascular disease (HR 1.99, 95%CI 1.17, 3.36), osteoporosis/osteoporotic fracture (HR 4.0, 95%CI 1.06, 15.08), pulmonary embolus (HR 4.35, 95%CI 1.53, 12.27), diverticulitis (HR 4.74, 95%CI 1.12, 2.09), and atherosclerosis (HR 9.73, 95%CI 3.22, 29.4). Comorbidity index suggested no difference between GCA patients and controls (age-adjusted mean difference =-0.1, p = 0.59). This is the first Australian study to determine the significant burden of GCA, particularly in the 12 months following diagnosis. Improved understanding of healthcare utilisation will enable appropriate resource allocation and research prioritisation to improve patient outcomes.